Cargando…
Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusion.
The dose limiting toxicities of the short infusion trial of the dacarbazine analog, CB10-277, were nausea and vomiting which appeared to be related to the peak plasma level of the parent drug. In addition, based on mouse studies, these dose limiting toxicities occurred at a less than optimal level o...
Autores principales: | Foster, B. J., Newell, D. R., Gumbrell, L. A., Jenns, K. E., Calvert, A. H. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1993
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968159/ https://www.ncbi.nlm.nih.gov/pubmed/8431368 |
Ejemplares similares
-
Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.
por: Foster, B. J., et al.
Publicado: (1993) -
A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma.
por: Bleehen, N. M., et al.
Publicado: (1994) -
Phase I and Pharmacokinetic Study of Paclitaxel by 24‐Hour Intravenous Infusion
por: Tamura, Tomohide, et al.
Publicado: (1994) -
Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours.
por: Desoize, B., et al.
Publicado: (1990) -
A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.
por: Paz-Ares, L., et al.
Publicado: (1998)